Irritable bowel syndrome is a complex disorder whose pathophysiology involves alterations in the enteric microbiota, visceral hypersensitivity, gut immune/barrier function, hypothalamic-pituitary-adrenal axis regulation, neurotransmitters, stress response, psychological factors, and more. The importance of diet in the management of irritable bowel syndrome has taken center stage in recent times as the literature validates the relationship of certain foods with the provocation of symptoms. Likewise, a number of elimination dietary programs have been successful in alleviating irritable bowel syndrome symptoms. Knowledge of the dietary management strategies for irritable bowel syndrome will help guide nutritionists and healthcare practitioners to deliver optimal outcomes. This tutorial reviews the nutrition management strategies for irritable bowel syndrome.
ChoungRSLockeGRIII. Epidemiology of IBS. Gastroenterol Clin North Am. 2011;40(1):1-10.
2.
DrossmanDAChangLBellamyN. Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Am J Gastroenterol. 2011;106(10):1749-1760.
3.
Maxion-BergemannSThieleckeFAbelFBergemannR. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics. 2006;24(1):21-37.
4.
MonnikesH. Quality of life in patients with irritable bowel syndrome. J Clin Gastroenterol. 2011;45(suppl):S98-S101.
5.
EswaranSTackJCheyWD. Food: the forgotten factor in the irritable bowel syndrome. Gastroenterol Clin North Am. 2011;40(1):141-162.
6.
FengBLaJHSchwartzESGebhartGF. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;302(10):G1085-G1098.
7.
CamilleriMLaschKZhouW. Irritable bowel syndrome: methods, mechanisms, and pathophysiology: the confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G775-G785.
8.
ZhouQVerneGN. New insights into visceral hypersensitivity—clinical implications in IBS. Nat Rev Gastroenterol Hepatol. 2011;8(6):349-355.
9.
O’MalleyDQuigleyEMDinanTGCryanJF. Do interactions between stress and immune responses lead to symptom exacerbations in irritable bowel syndrome?Brain Behav Immun. 2011;25(7):1333-1341.
10.
HaslerWL. Traditional thoughts on the pathophysiology of irritable bowel syndrome. Gastroenterol Clin North Am. 2011;40(1):21-43.
11.
Surdea-BlagaTBabanADumitrascuDL. Psychosocial determinants of irritable bowel syndrome. World J Gastroenterol. 2012;18(7):616-626.
12.
CamilleriMKatzkaDA. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;302(10):G1075-G1084.
ShahEDBasseriRJChongKPimentelM. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55(9):2441-2449.
15.
LeeHRPimentelM. Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth. Curr Gastroenterol Rep. 2006;8(4):305-311.
BarbaraGCremonCCariniG. The immune system in irritable bowel syndrome. J Neurogastroenterol Motil. 2011;17(4):349-359.
18.
FordACTalleyNJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011;46(4):421-431.
19.
JonesVAMcLaughlanPShorthouseMWorkmanEHunterJO. Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. Lancet. 1982;2(8308):1115-1117.
20.
MullinGE. Food allergy and irritable bowel syndrome. JAMA. 1991;265(13):1736.
21.
ShepherdSJParkerFCMuirJGGibsonPR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008;6(7):765-771.
22.
SimonatoBDe LazzariFPasiniG. IgE binding to soluble and insoluble wheat flour proteins in atopic and non-atopic patients suffering from gastrointestinal symptoms after wheat ingestion. Clin Exp Allergy. 2001;31(11):1771-1778.
23.
BohnLStorsrudSTornblomHBengtssonUSimrenM. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol. 2013;108(5):634-641.
24.
RedingKWCainKCJarrettMEEugenioMDHeitkemperMM. Relationship between patterns of alcohol consumption and gastrointestinal symptoms among patients with irritable bowel syndrome. Am J Gastroenterol. 2013;108(2):270-276.
25.
HeizerWDSouthernSMcGovernS. The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review. J Am Diet Assoc. 2009;109(7):1204-1214.
26.
YangCMLiYQ. The therapeutic effects of eliminating allergic foods according to food-specific IgG antibodies in irritable bowel syndrome [in Chinese]. Zhonghua Nei Ke Za Zhi. 2007;46(8):641-643.
27.
DriskoJBischoffBHallMMcCallumR. Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics. J Am Coll Nutr. 2006;25(6):514-522.
28.
ZarSMincherLBensonMJKumarD. Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome. Scand J Gastroenterol. 2005;40(7):800-807.
29.
HunterJO. Food elimination in IBS: the case for IgG testing remains doubtful. Gut. 2005;54(8):1203.
30.
ZarSBensonMJKumarD. Food-specific serum IgG4 and IgE titers to common food antigens in irritable bowel syndrome. Am J Gastroenterol. 2005;100(7):1550-1557.
31.
FlochMH. Use of diet and probiotic therapy in the irritable bowel syndrome: analysis of the literature. J Clin Gastroenterol. 2005;39(5)(suppl 3):S243-S246.
32.
AtkinsonWSheldonTAShaathNWhorwellPJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut. 2004;53(10):1459-1464.
33.
ZarSKumarDKumarD. Role of food hypersensitivity in irritable bowel syndrome. Minerva Med. 2002;93(5):403-412.
34.
AydinlarEIDikmenPYTiftikciA. IgG-based elimination diet in migraine plus irritable bowel syndrome. Headache. 2013;53(3):514-525.
35.
GuoHJiangTWangJChangYGuoHZhangW. The value of eliminating foods according to food-specific immunoglobulin G antibodies in irritable bowel syndrome with diarrhoea. J Int Med Res. 2012;40(1):204-210.
36.
SchaubschlagerWWBeckerWMSchadeUZabelPSchlaakM. Release of mediators from human gastric mucosa and blood in adverse reactions to benzoate. Int Arch Allergy Appl Immunol. 1991;96(2):97-101.
37.
SampsonHA. In vitro diagnosis and mediator assays for food allergies. Allergy Proc. 1993;14(4):259-261.
38.
MullinGESwiftKMLipskiLTurnbullLKRampertabSD. Testing for food reactions: the good, the bad, and the ugly. Nutr Clin Pract. 2010;25(2):192-198.
39.
StapelSOAseroRBallmer-WeberBK. Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI Task Force Report. Allergy. 2008;63(7):793-796.
40.
StefaniniGFSaggioroAAlvisiV. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type: multicenter study of 428 patients. Scand J Gastroenterol. 1995;30(6):535-541.
ZuoXLLiYQLiWJ. Alterations of food antigen-specific serum immunoglobulins G and E antibodies in patients with irritable bowel syndrome and functional dyspepsia. Clin Exp Allergy. 2007;37(6):823-830.
43.
BengtssonUNilsson-BalknasUHansonLAAhlstedtS. Double blind, placebo controlled food reactions do not correlate to IgE allergy in the diagnosis of staple food related gastrointestinal symptoms. Gut. 1996;39(1):130-135.
44.
LewisPJ. Management of the irritable bowel syndrome: food intolerance may play a part. BMJ. 1995;310(6986):1067.
45.
GrazioliIMelziGBalsamoV. Food intolerance and irritable bowel syndrome of childhood: clinical efficacy of oral sodium cromoglycate and elimination diet [in Italian]. Minerva Pediatr. 1993;45(6):253-258.
46.
AustinGLDaltonCBHuY. A very low-carbohydrate diet improves symptoms and quality of life in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009;7(6):706-708.e1.
47.
FordACCheyWDTalleyNJMalhotraASpiegelBMMoayyediP. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med. 2009;169(7):651-658.
48.
CashBDRubensteinJHYoungPKGentryANojkovBLeeDAndrewsAHDobhanRCheyWD. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroent2011;141:1187-1193.
49.
SainsburyASandersDSFordAC. Prevalence of irritable bowel syndrome–type symptoms in patients with celiac disease: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(4):359-365.e1.
50.
VoltaUCaioGTovoliFDe GiorgioR. Non-celiac gluten sensitivity: questions still to be answered despite increasing awareness. Cell Mol Immunol. 2013;10(5):383-392.
51.
CarroccioABruscaIMansuetoP. Fecal assays detect hypersensitivity to cow’s milk protein and gluten in adults with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2011;9(11):965-971.e3.
52.
VerduEFArmstrongDMurrayJA. Between celiac disease and irritable bowel syndrome: the “no man’s land” of gluten sensitivity. Am J Gastroenterol. 2009;104(6):1587-1594.
53.
WahnschaffeUSchulzkeJDZeitzMUllrichR. Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2007;5(7):844-850, quiz 769.
54.
BiesiekierskiJRNewnhamEDIrvingPM. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol. 2011;106(3):508-515.
55.
Vazquez-RoqueMICamilleriMSmyrkT. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology. 2013;144(5):903-911.e3.
56.
BiesiekierskiJRPetersSLNewnhamEDRosellaOMuirJGGibsonPR. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology. 2013;145(2):320-328.e1-3.
57.
CarroccioAMansuetoPIaconoG. Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol. 2012;107(12):1898-1906.
58.
O’ConnellSWalshG. Physicochemical characteristics of commercial lactases relevant to their application in the alleviation of lactose intolerance. Appl Biochem Biotechnol. 2006;134(2):179-91.
59.
AkramMHamidA. Mini review on fructose metabolism. Obes Res Clin Pract. 2013;7(2):e89-e94.
60.
SkoogSMBharuchaAE. Dietary fructose and gastrointestinal symptoms: a review. Am J Gastroenterol. 2004;99(10):2046-2050.
61.
VosMBKimmonsJEGillespieCWelshJBlanckHM. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med. 2008;10(7):160.
62.
ChoiYKKraftNZimmermanBJacksonMRaoSS. Fructose intolerance in IBS and utility of fructose-restricted diet. J Clin Gastroenterol. 2008;42(3):233-238.
63.
SachdevaSRawatAKReddyRSPuriAS. Small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome: frequency and predictors. J Gastroenterol Hepatol. 2011;26(suppl 3):135-138.
64.
Reyes-HuertaJUdelaCruz-PatinoERamirez-GutierrezdeVelascoAZamudioCRemes-TrocheJM. Fructose intolerance in patients with irritable bowel syndrome: a case-control study [in Spanish]. Rev Gastroenterol Mex. 2010;75(4):405-411.
65.
ShepherdSJLomerMCGibsonPR. Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol. 2013;108(5):707-717.
66.
BarrettJSGibsonPR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals?Ther Adv Gastroenterol. 2012;5(4):261-268.
67.
van der WaaijLAStevensJ. The low FODMAP diet as a therapy for irritable bowel syndrome [in Dutch]. Ned Tijdschr Geneeskd. 2014;158:A7407.
68.
OngDKMitchellSBBarrettJS. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol. 2010;25(8):1366-1373.
69.
StaudacherHMWhelanKIrvingPMLomerMC. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet. 2011;24(5):487-495.
70.
HalmosEPPowerVAShepherdSJGibsonPRMuirJG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75.e5.
71.
DrossmanDAMorrisCBSchneckS. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43(6):541-550.
72.
HaasLMcClainCVarilekG. Complementary and alternative medicine and gastrointestinal diseases. Curr Opin Gastroenterol. 2000;16(2):188-196.
73.
KongSCHurlstoneDPPocockCY. The incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol. 2005;39(2):138-141.
74.
SchillerJSLucasJWWardBWPeregoyJA. Summary health statistics for U.S. adults: National Health Interview Survey, 2010. Vital Health Stat. 2012;10(252):1-207.
75.
MehtaDHGardinerPMPhillipsRSMcCarthyEP. Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions. J Altern Complement Med. 2008;14(10):1263-1269.
76.
PirottaM. Irritable bowel syndrome—the role of complementary medicines in treatment. Aust Fam Physician. 2009;38(12):966-968.
77.
WangZJLiHXWangJHZhangF. Effect of Shugan Jianpi Granule on gut mucosal serotonin-positive cells in patients with irritable bowel syndrome of stagnated Gan-qi attacking Pi syndrome type. Chin J Integr Med. 2008;14(3):185-189.
78.
BensoussanATalleyNJHingMMenziesRGuoANguM. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA. 1998;280(18):1585-1589.
79.
LeungWKWuJCLiangSM. Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial. Am J Gastroenterol. 2006;101(7):1574-1580.
80.
SallonSBen-AryeEDavidsonRShapiroHGinsbergGLigumskyM. A novel treatment for constipation-predominant irritable bowel syndrome using Padma Lax, a Tibetan herbal formula. Digestion. 2002;65(3):161-171.
81.
WangGLiTQWangL. Tong-xie-ning, a Chinese herbal formula, in treatment of diarrhea-predominant irritable bowel syndrome: a prospective, randomized, double-blind, placebo-controlled trial. Chin Med J (Engl). 2006;119(24):2114-2119.
82.
BianZWuTLiuL. Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review. J Altern Complement Med. 2006;12(4):401-407.
83.
WegenerTWagnerH. The active components and the pharmacological multi-target principle of STW 5 (Iberogast). Phytomedicine. 2006;13(suppl 5):20-35.
84.
SimmenUKelberOOkpanyiSNJaeggiRBueterBWeiserD. Binding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine. 2006;13(suppl 5):51-55.
85.
OttillingerBStorrMMalfertheinerPAllescherHD. STW 5 (Iberogast®)—a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr. 2013;163(3-4):65-72.
86.
PatrickL. Gastroesophageal reflux disease (GERD): a review of conventional and alternative treatments. Altern Med Rev. 2011;16(2):116-133.
87.
SibaevAYueceBKelberO. STW 5 (Iberogast) and its individual herbal components modulate intestinal electrophysiology of mice. Phytomedicine. 2006;13(suppl 5):80-89.
88.
WaldARakelD. Behavioral and complementary approaches for the treatment of irritable bowel syndrome. Nutr Clin Pract. 2008;23(3):284-292.
89.
Ferracioli-OdaEQawasmiABlochMH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773.
90.
ThorPJKrolczykGGilKZurowskiDNowakL. Melatonin and serotonin effects on gastrointestinal motility. J Physiol Pharmacol. 2007;58(suppl 6):97-103.
91.
CalvoJRGonzalez-YanesCMaldonadoMD. The role of melatonin in the cells of the innate immunity: a review. J Pineal Res. 2013;55(2):103-120.
92.
ReiterRJTanDXOsunaCGittoE. Actions of melatonin in the reduction of oxidative stress: a review. J Biomed Sci. 2000;7(6):444-458.
93.
RadwanPSkrzydlo-RadomanskaBRadwan-KwiatekKBurak-CzapiukBStrzemeckaJ. Is melatonin involved in the irritable bowel syndrome?J Physiol Pharmacol. 2009;60(suppl 3):67-70.
94.
Wisniewska-JarosinskaMChojnackiJKonturekSBrzozowskiTSmigielskiJChojnackiC. Evaluation of urinary 6-hydroxymelatonin sulphate excretion in women at different age with irritable bowel syndrome. J Physiol Pharmacol. 2010;61(3):295-300.
95.
LuWZGweeKAMoochhallaSHoKY. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2005;22(10):927-934.
96.
LuWZSongGHGweeKAHoKY. The effects of melatonin on colonic transit time in normal controls and IBS patients. Dig Dis Sci. 2009;54(5):1087-1093.
97.
SahaLMalhotraSRanaSBhasinDPandhiP. A preliminary study of melatonin in irritable bowel syndrome. J Clin Gastroenterol. 2007;41(1):29-32.
98.
SongGHLengPHGweeKAMoochhalaSMHoKY. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut. 2005;54(10):1402-1407.
99.
Sanchez-BarceloEJMediavillaMDTanDXReiterRJ. Clinical uses of melatonin: evaluation of human trials. Curr Med Chem. 2010;17(19):2070-2095.
100.
MarakisGWalkerAFMiddletonRWBoothJCWrightJPikeDJ. Artichoke leaf extract reduces mild dyspepsia in an open study. Phytomedicine. 2002;9(8):694-699.
101.
JoyJFHaberSL. Clinical uses of artichoke leaf extract. Am J Health Syst Pharm. 2007;64(18):1904, 1906-1909.
102.
MengSCaoJFengQPengJHuY. Roles of chlorogenic acid on regulating glucose and lipids metabolism: a review. Evid Based Complement Alternat Med. 2013;2013:801457.
103.
MinBRSolaimanSShangeREunJS. Gastrointestinal bacterial and methanogenic archaea diversity dynamics associated with condensed tannin-containing pine bark diet in goats using 16S rDNA amplicon pyrosequencing. Int J Microbiol. 2014;2014:141909.
104.
GrigoleitHGGrigoleitP. Peppermint oil in irritable bowel syndrome. Phytomedicine. 2005;12(8):601-606.
105.
PittlerMHErnstE. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol. 1998;93(7):1131-1135.
106.
KhannaRMacdonaldJKLevesqueBG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48(6):505-512.
107.
MullinGEClarkeJO. Role of complementary and alternative medicine in managing gastrointestinal motility disorders. Nutr Clin Pract. 2010;25(1):85-87.
108.
HikiN. Peppermint oil reduces gastric motility during the upper gastrointestinal endoscopy [in Japanese]. Nihon Rinsho. 2010;68(11):2126-2134.
109.
MicklefieldGJungOGrevingIMayB. Effects of intraduodenal application of peppermint oil (WS(R) 1340) and caraway oil (WS(R) 1520) on gastroduodenal motility in healthy volunteers. Phytother Res. 2003;17(2):135-140.
110.
AlamMSRoyPKMiahAR. Efficacy of Peppermint oil in diarrhea predominant IBS—a double blind randomized placebo-controlled study. Mymensingh Med J. 2013;22(1):27-30.
111.
HarveyRFPomareEWHeatonKW. Effects of increased dietary fibre on intestinal transit. Lancet. 1973;1(7815):1278-1280.
112.
KobayakawaASuzukiTIkamiTSaitoMYabeDSeinoY. Improvement of fasting plasma glucose level after ingesting moderate amount of dietary fiber in Japanese men with mild hyperglycemia and visceral fat obesity. J Diet Suppl. 2013;10(2):129-141.
113.
QuarteroAOMeineche-SchmidtVMurisJRubinGde WitN. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2005;(2):CD003460.
114.
RuepertLQuarteroAOde WitNJvan der HeijdenGJRubinGMurisJW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;(8):CD003460.
115.
ChouinardLE. The role of psyllium fibre supplementation in treating irritable bowel syndrome. Can J Diet Pract Res. 2011;72(1):e107-e14.
116.
FordACTalleyNJSpiegelBM. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337:a2313.
117.
GibsonGRRoberfroidMB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125(6):1401-1412.
118.
CoxamV. Current data with inulin-type fructans and calcium, targeting bone health in adults. J Nutr. 2007;137(11)(suppl):2527S-2533S.
119.
KönigJBrummerRJ. Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome. Benef Microbes. 2014;5(3):247-261.
120.
HavenaarR. Intestinal health functions of colonic microbial metabolites: a review. Benef Microbes. 2011;2(2):103-114.
121.
Wilcz-VillegaEMcCleanSO’SullivanM. Reduced E-cadherin expression is associated with abdominal pain and symptom duration in a study of alternating and diarrhea predominant IBS. Neurogastroenterol Motil. 2014;26(3):316-325.
122.
GuarnerFKhanAGGarischJ. World Gastroenterology Organisation global guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol. 2012;46(6):468-481.
123.
PicheTdes VarannesSBSacher-HuvelinSHolstJJCuberJCGalmicheJP. Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. Gastroenterology. 2003;124(4):894-902.
124.
RoberfroidMGibsonGRHoylesL. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010;104(suppl 2):S1-S63.
125.
LeyRETurnbaughPJKleinSGordonJI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022-1023.
126.
CaniPDLecourtEDewulfEM. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr. 2009;90(5):1236-1243.
127.
KajiIKarakiSTanakaRKuwaharaA. Density distribution of free fatty acid receptor 2 (FFA2)–expressing and GLP-1-producing enteroendocrine L cells in human and rat lower intestine, and increased cell numbers after ingestion of fructo-oligosaccharide. J Mol Histol. 2011;42(1):27-38.
128.
FuretJPKongLCTapJ. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010;59(12):3049-3057.
129.
PaineauDPayenFPanserieuS. The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br J Nutr. 2008;99(2):311-318.
130.
SilkDBDavisAVulevicJTzortzisGGibsonGR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29(5):508-518.
131.
HunterJOTuffnellQLeeAJ. Controlled trial of oligofructose in the management of irritable bowel syndrome. J Nutr. 1999;129(7)(suppl):1451S-1453S.
132.
WhelanK. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care. 2011;14(6):581-587.
133.
OlesenMGudmand-HoyerE. Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. Am J Clin Nutr. 2000;72(6):1570-1575.
134.
RosaniaRGiorgioFPrincipiM. Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation. Curr Clin Pharmacol. 2013;8(2):169-172.
135.
SanzY. Effects of a gluten-free diet on gut microbiota and immune function in healthy adult humans. Gut Microbes. 2010;1(3):135-137.
136.
CollinsSM. A role for the gut microbiota in IBS [published online April 22, 2014]. Nat Rev Gastroenterol Hepatol.
137.
GroupNHWPetersonJGargesS. The NIH Human Microbiome Project. Genome Res. 2009;19(12):2317-2323.
138.
HongSNRheePL. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastroenterol. 2014;20(10):2470-2481.
139.
QuigleyEM. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. J Dig Dis. 2007;8(1):2-7.
140.
QuigleyEMBytzerPJonesRMearinF. Irritable bowel syndrome: the burden and unmet needs in Europe. Dig Liver Dis. 2006;38(10):717-723.
141.
QuigleyEMFlourieB. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil. 2007;19(3):166-172.
142.
WhelanKQuigleyEM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol. 2013;29(2):184-189.
143.
McFarlandLVDublinS. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008;14(17):2650-2661.
144.
MoayyediPFordACTalleyNJ. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325-332.
145.
HoveydaNHeneghanCMahtaniKRPereraRRobertsNGlasziouP. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol. 2009;9:15.
146.
Huertas-CeballosAALoganSBennettCMacarthurC. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database Syst Rev. 2009;(1):CD003019.
147.
BrennerDMMoellerMJCheyWDSchoenfeldPS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104(4):1033-1050.
148.
National Institute for Health and Clinical Excellence (NICE). Irritable Bowel Syndrome in Adults: Diagnosis and Management of Irritable Bowel Syndrome in Primary Care. London, UK: NICE; 2008.
149.
Rodriguez-CabezasMEGalvezJCamuescoD. Intestinal anti-inflammatory activity of dietary fiber (Plantago ovata seeds) in HLA-B27 transgenic rats. Clin Nutr. 2003;22(5):463-471.
150.
FlochMHWalkerWAMadsenK. Recommendations for probiotic use—2011 update. J Clin Gastroenterol. 2011;45(suppl):S168-S171.
151.
LigaardenSCAxelssonLNaterstadKLydersenSFarupPG. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterol. 2010;10:16.
152.
MullinGE. Probiotics and digestive disease. Nutr Clin Pract. 2012;27(2):300-302.
153.
FordACSpiegelBMTalleyNJMoayyediP. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279-1286.
154.
SandersMEAkkermansLMHallerD. Safety assessment of probiotics for human use. Gut Microbes. 2010;1(3):164-185.
155.
McKenzieY.A.AlderA.AndersonW.WillsA.GoddardL.GuliaP.JankovichE.MutchP.ReevesL.B.SingerA.LomerM.C.E.on behalf of Gastroenterology Specialist Group of the British Dietetic Association. (2012) British Dietetic Association evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults. J Hum Nutr Diet. 25, 260–274 doi:10.1111/j.1365-277X.2012.01242.x
156.
The American College of Gastroenterology Task Force on IBS. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104:S1-S35.
157.
Rubio-TapiaAHillIDKellyCPCalderwoodAHMurrayJA. Diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108:656-676.
158.
KalraEK. Nutraceutical- definition and introduction. AAPS PharmSci2003; 5(3) Article 25. Available from http://www.pharmsci.org
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
